Search hospitals
>
Tennessee
>
Nashville
Vanderbilt-Ingram Cancer Center
Claim this profile
Nashville, Tennessee 37212
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
1090 reported clinical trials
68 medical researchers
Summary
Vanderbilt-Ingram Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Vanderbilt-Ingram Cancer Center is involved with conducting 1,090 clinical trials across 858 conditions. There are 68 research doctors associated with this hospital, such as Scott Borinstein, M.D., Michael Gibson, Elizabeth J. Davis, and Debra L. Friedman.
Area of expertise
Cancer
Vanderbilt-Ingram Cancer Center has run 182 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Vanderbilt-Ingram Cancer Center has run 128 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Scott Borinstein, M.D.
Vanderbilt University/Ingram Cancer Center
8 years of reported clinical research
Michael Gibson
Vanderbilt University/Ingram Cancer Center
5 years of reported clinical research
Elizabeth J. Davis
Vanderbilt University/Ingram Cancer Center
6 years of reported clinical research
Debra L. Friedman
Vanderbilt University/Ingram Cancer Center
6 years of reported clinical research
Clinical Trials running at Vanderbilt-Ingram Cancer Center
Lung Cancer
Cancer
Skin Cancer
Kidney Cancer
Breast Cancer
Ovarian Cancer
Colorectal Cancer
Prostate Cancer
Multiple Myeloma
Solid Tumors
N-803 + Tislelizumab + Docetaxel
for Non-Small Cell Lung Cancer
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. Participant randomization will be stratified by geographical region (North America vs Europe vs ASIA vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA); (epidermal growth factor receptor \[EGFR\]/anaplastic lymphoma kinase \[ALK\] vs OTHER AGA vs No AGA).
Recruiting
2 awards
Phase 3
5 criteria
Radiotherapy
for Lung Cancer
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vanderbilt-Ingram Cancer Center?
Vanderbilt-Ingram Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Vanderbilt-Ingram Cancer Center is involved with conducting 1,090 clinical trials across 858 conditions. There are 68 research doctors associated with this hospital, such as Scott Borinstein, M.D., Michael Gibson, Elizabeth J. Davis, and Debra L. Friedman.
Where is Vanderbilt-Ingram Cancer Center located?
**Vanderbilt-Ingram Cancer Center** - **Location:** 2220 Pierce Avenue, Nashville, TN. - **Parking:** South Garage, 1504 24th Ave. S., Nashville, TN 37212.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Vanderbilt-Ingram Cancer Center, call 1-877-936-8422 or visit their [financial assistance page](http://www.vanderbilthealth.com/information/financial-assistance) for details on their policy and payment plan options. They provide a plain language summary of their financial assistance program. For insurance inquiries, visit the [Vanderbilt Health Insurance office](http://www.vanderbilt.edu/financialaid/faforms/vandyhealthwaiver.php).
What insurance does Vanderbilt-Ingram Cancer Center accept?
The Vanderbilt-Ingram Cancer Center accepts a variety of insurance plans, including but not limited to Aetna, Aetna Better Health (KY Medicaid), Ambetter of Tennessee (Commercial), BlueCross BlueShield, Cigna, and UnitedHealthcare. It's important to contact your insurance provider to confirm coverage for services at Vanderbilt facilities. Note: Vanderbilt Health is out of network for Humana's Medicare Advantage HMO and Humana Kentucky Medicaid - Health Horizons as of April 16, 2023.
What awards or recognition has Vanderbilt-Ingram Cancer Center received?
Vanderbilt-Ingram Cancer Center, located in Nashville, Tennessee, is recognized as a Comprehensive Cancer Center by the National Cancer Institute (NCI), the only one in Tennessee offering research and care for both adults and children with cancer. It is a member of the National Comprehensive Cancer Network (NCCN) and a Lead Academic Participating Site in the NCI's National Clinical Trials Network (NCTN). The center secures approximately $142 million annually in research support and holds two NCI Specialized Programs of Research Excellence (SPORE) grants for gastrointestinal (GI) and breast cancers.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.